EP1189609A4 - Antagonistes du recepteur cxcr-4 et mimetiques de thrombopoietine - Google Patents

Antagonistes du recepteur cxcr-4 et mimetiques de thrombopoietine

Info

Publication number
EP1189609A4
EP1189609A4 EP00928735A EP00928735A EP1189609A4 EP 1189609 A4 EP1189609 A4 EP 1189609A4 EP 00928735 A EP00928735 A EP 00928735A EP 00928735 A EP00928735 A EP 00928735A EP 1189609 A4 EP1189609 A4 EP 1189609A4
Authority
EP
European Patent Office
Prior art keywords
cxcr
receptor antagonists
thrombopoietin mimetics
thrombopoietin
mimetics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00928735A
Other languages
German (de)
English (en)
Other versions
EP1189609A1 (fr
Inventor
Juan I Luengo
Alan Thomas Price
Antony Shaw
Kenneth Wiggall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1189609A1 publication Critical patent/EP1189609A1/fr
Publication of EP1189609A4 publication Critical patent/EP1189609A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Vascular Medicine (AREA)
EP00928735A 1999-05-03 2000-05-03 Antagonistes du recepteur cxcr-4 et mimetiques de thrombopoietine Withdrawn EP1189609A4 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US13218999P 1999-05-03 1999-05-03
US13218599P 1999-05-03 1999-05-03
US13219499P 1999-05-03 1999-05-03
US132194P 1999-05-03
US132185P 1999-05-03
US132189P 1999-05-03
PCT/US2000/011951 WO2000066112A1 (fr) 1999-05-03 2000-05-03 Antagonistes du recepteur cxcr-4 et mimetiques de thrombopoietine

Publications (2)

Publication Number Publication Date
EP1189609A1 EP1189609A1 (fr) 2002-03-27
EP1189609A4 true EP1189609A4 (fr) 2002-10-30

Family

ID=27384258

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00928735A Withdrawn EP1189609A4 (fr) 1999-05-03 2000-05-03 Antagonistes du recepteur cxcr-4 et mimetiques de thrombopoietine

Country Status (4)

Country Link
EP (1) EP1189609A4 (fr)
JP (1) JP2002543126A (fr)
AU (1) AU4692400A (fr)
WO (1) WO2000066112A1 (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2245224A1 (fr) 1998-08-14 2000-02-14 Jiang-Hong Giong Antagonistes du recepteur de la chimiokine et chimiotherapie
CA2305787A1 (fr) 2000-05-09 2001-11-09 The University Of British Columbia Traitement antagoniste cxcr4 de cellules hematopoietiques
WO1999047158A2 (fr) 1998-03-13 1999-09-23 The University Of British Columbia Antagonistes therapeutiques du recepteur de chemokine
DE60042030D1 (de) * 1999-12-17 2009-05-28 Genzyme Corp Chemokinrezeptor-bindende heterocyclische verbindungen
US7378098B2 (en) 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
JP2004501083A (ja) 2000-04-18 2004-01-15 アゴーロン・ファーマシューティカルズ・インコーポレイテッド プロテインキナーゼを阻害するためのピラゾール
DE60103052T2 (de) * 2000-05-09 2005-03-03 The University Of British Columbia, Vancouver Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
TWI282785B (en) 2000-05-30 2007-06-21 Chugai Pharmaceutical Co Ltd A compound having thrombopoietin-like activities
ES2380009T3 (es) * 2001-07-31 2012-05-07 Genzyme Global S.A.R.L. Métodos para movilizar las células madre/progenitoras
US20050233991A1 (en) * 2002-03-20 2005-10-20 Ravi Salgia Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
CA2495184A1 (fr) 2002-08-14 2004-02-26 Nissan Chemical Industries, Ltd. Activateurs du recepteur de la thrombopoietine et procede de production
TWI324593B (en) 2002-10-09 2010-05-11 Nissan Chemical Ind Ltd Pyrazolone compounds and thrombopoietin receptor activator
WO2004080966A1 (fr) 2003-03-14 2004-09-23 Ono Pharmaceutical Co., Ltd. Derives heterocycliques renfermant de l'azote et medicaments contenant ces derives comme principe actif
EP1608352B1 (fr) 2003-04-02 2009-12-30 Taigen Biotechnology Composes polyamine pour le traitement de maladies induites par le recepteur de la chemokine
US7504422B2 (en) 2003-04-02 2009-03-17 Taigen Biotechnology Co. Ltd. Polyamine compounds
US7498323B2 (en) 2003-04-18 2009-03-03 Ono Pharmaceuticals Co., Ltd. Spiro-piperidine compounds and medicinal use thereof
EP2387998A1 (fr) * 2003-04-29 2011-11-23 Glaxosmithkline LLC Procédés de traitement de maladies/lésions dégénératives
DE10342503A1 (de) * 2003-09-12 2005-04-14 Merck Patent Gmbh Benzyl-Benzimidazolylderivate
WO2005051927A1 (fr) * 2003-11-26 2005-06-09 Kureha Corporation Procede de culture de lymphocytes t cd4 positifs par l'intermediaire d'une culture de vih-1, et inhibiteur de croissance du vih-1
PT1699455E (pt) * 2003-12-15 2013-08-27 Merck Sharp & Dohme Inibidores de protease de aspartilo heterocíclicos
WO2005103721A1 (fr) * 2004-04-20 2005-11-03 Bayer Healthcare Ag Moyens diagnostiques et therapeutiques pour maladies associees au recepteur 4 de la chimiokine cxc (cxcr4)
EP1790637B1 (fr) 2004-09-13 2014-01-29 Ono Pharmaceutical Co., Ltd. Dérivés de N-4-piperidylurée et medicaments les contenant comme principe actif
US8552031B2 (en) 2004-12-08 2013-10-08 Nissan Chemical Industries, Ltd. 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
AU2005314788B2 (en) 2004-12-14 2011-09-22 Nissan Chemical Industries, Ltd. Amide compound and thrombopoietin receptor activator
US7501526B2 (en) 2005-01-20 2009-03-10 Taigen Biotechnology Synthesis of polyamine compounds
US20110052612A1 (en) 2005-05-31 2011-03-03 Ono Pharmaceutical Co., Ltd. Spiropiperidine compound and medicinal use thereof
NZ563202A (en) 2005-07-15 2011-02-25 Nissan Chemical Ind Ltd Thiophene compounds and thrombopoietin receptor activators
KR101290484B1 (ko) 2005-07-20 2013-07-26 닛산 가가쿠 고교 가부시키 가이샤 피라졸 화합물 및 트롬보포이에틴 수용체 활성화제
PT1942108E (pt) 2005-10-28 2013-10-24 Ono Pharmaceutical Co Composto com um grupo básico e a sua utilização
EP1947101A4 (fr) 2005-11-07 2009-09-16 Nissan Chemical Ind Ltd Composé de type hydrazide et activateur du récepteur de la thrombopoïétine
WO2007058322A1 (fr) 2005-11-18 2007-05-24 Ono Pharmaceutical Co., Ltd. Composé contenant un groupe basique et son utilisation
KR20090008217A (ko) 2006-03-10 2009-01-21 오노 야꾸힝 고교 가부시키가이샤 질소 함유 복소환 유도체 및 이들을 유효 성분으로 하는 약제
EP2042503B1 (fr) 2006-05-16 2013-01-30 Ono Pharmaceutical Co., Ltd. Composé ayant un groupe acide qui peut être protégé et utilisation dudit composé
EP2025671A4 (fr) 2006-06-07 2011-04-06 Nissan Chemical Ind Ltd Composé hétérocyclique azoté et activateur de récepteur de thrombopoïétine
WO2008016006A1 (fr) 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Composé auquel un groupe cyclique est lié par une liaison spiro et son utilisation
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
WO2010129351A1 (fr) 2009-04-28 2010-11-11 Schepens Eye Research Institute Procédé pour identifier et pour traiter une dégénérescence maculaire liée à l'âge
US8609672B2 (en) 2010-08-27 2013-12-17 University Of The Pacific Piperazinylpyrimidine analogues as protein kinase inhibitors
WO2012102937A2 (fr) 2011-01-25 2012-08-02 Irm Llc Composés qui développent des cellules souches hématopoïétiques
CA2858069C (fr) 2011-12-08 2020-02-11 Novartis Ag Compositions et procedes pour la generation amelioree de cellules souches/progenitrices hematopoietiques
PT2807165T (pt) 2012-01-27 2019-07-12 Univ Montreal Derivados de pirimido[4,5-b]indole e sua utilização na expansão de células estaminais hematopoiéticas
NZ714283A (en) * 2013-05-10 2020-04-24 Karus Therapeutics Ltd Novel histone deacetylase inhibitors
CA2946446C (fr) 2014-04-22 2020-11-03 Universite De Montreal Composes de pyrido-pyrrolo-pyrimidine et de pyrido-indole, compositions pharmaceutiques contenant ces composes et leur utilisation dans l'expansion de cellules souches hematopoietiques et/ou de cellules progenitrices hematopoietiques
CA2966150A1 (fr) 2014-10-31 2016-05-06 Nissan Chemical Industries, Ltd. Fibre de liaison de ligand et substrat de culture cellulaire utlisant ladite fibre
ES2754549T3 (es) * 2014-12-03 2020-04-20 Glycomimetics Inc Inhibidores heterobifuncionales de E-selectinas y receptores de quimioquinas CXCR4
AU2016307752B2 (en) * 2015-08-17 2020-11-12 Southwestern Oklahoma State University Compositions comprising macrocycle derivatives incorporating bridged macrocycles and methods of producing and using same
WO2017151708A1 (fr) 2016-03-02 2017-09-08 Glycomimetics, Inc. Méthodes pour le traitement et/ou à la prévention de maladies cardiovasculaires par inhibition de la sélectine e
EP3471716A1 (fr) * 2016-06-16 2019-04-24 Centre National De La Recherche Scientifique Composés de liaison au récepteur cxcr4 utiles pour augmenter le taux d'interféron
EP3497131B1 (fr) 2016-08-08 2022-03-09 GlycoMimetics, Inc. Combinaison d'inhibiteurs des points de contrôle des lymphocytes t avec des inhibiteurs de e-sélectine ou de cxcr4, ou avec des inhibiteurs hétérobifonctionnels de e-sélectine et de cxcr4
US11072625B2 (en) 2016-10-07 2021-07-27 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists
CA3054605A1 (fr) 2017-03-15 2018-09-20 Glycomimetics, Inc. Derives de galactopyranosyle-cyclohexyle utilises en tant qu'antagonistes d'e-selectine
WO2019108750A1 (fr) 2017-11-30 2019-06-06 Glycomimetics, Inc. Méthodes de mobilisation de lymphocytes infiltrant la moelle et leurs utilisations
CN111566117A (zh) 2017-12-29 2020-08-21 糖模拟物有限公司 E-选择蛋白和半乳凝素-3的异双功能抑制剂
WO2019173229A1 (fr) 2018-03-05 2019-09-12 Glycomimetics, Inc. Méthodes de traitement de la leucémie aiguë myéloïde et d'états pathologiques associés
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
US11564913B2 (en) 2019-05-03 2023-01-31 Children's Hospital Medical Center Compositions and methods for treating cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0427595A1 (fr) * 1989-11-09 1991-05-15 L'air Liquide, Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude Procédé de synthèse de dérivés polyazotés cycliques
WO1992016494A1 (fr) * 1991-03-15 1992-10-01 Johnson Matthey Plc Composes antiviraux a longue chaine
US5369107A (en) * 1989-08-07 1994-11-29 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives, processes for production thereof and pharmaceutical compositions comprising the same
WO1996030349A1 (fr) * 1995-03-30 1996-10-03 Johnson Matthey Plc Procede de preparation de 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
WO1999022734A1 (fr) * 1997-10-31 1999-05-14 Smithkline Beecham Corporation Nouveaux complexes metalliques

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9511357D0 (en) * 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369107A (en) * 1989-08-07 1994-11-29 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives, processes for production thereof and pharmaceutical compositions comprising the same
EP0427595A1 (fr) * 1989-11-09 1991-05-15 L'air Liquide, Societe Anonyme Pour L'etude Et L'exploitation Des Procedes Georges Claude Procédé de synthèse de dérivés polyazotés cycliques
WO1992016494A1 (fr) * 1991-03-15 1992-10-01 Johnson Matthey Plc Composes antiviraux a longue chaine
WO1996030349A1 (fr) * 1995-03-30 1996-10-03 Johnson Matthey Plc Procede de preparation de 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
WO1999022734A1 (fr) * 1997-10-31 1999-05-14 Smithkline Beecham Corporation Nouveaux complexes metalliques

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ARAKAKI, RIEKO ET AL: "T134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure", JOURNAL OF VIROLOGY (1999), 73(2), 1719-1723, XP002199036 *
BRANDES, STEPHANE ET AL: "New facile and convenient synthesis of bispolyazamacrocycles using Boc protection. Determination of geometric parameters of dinuclear copper(II) complexes using ESR spectroscopy and molecular mechanics calculations", BULL. SOC. CHIM. FR. (1996), 133(1), 65-73, XP000196380 *
DESSOLIN, JEAN ET AL: "New Bicyclam-AZT Conjugates: Design, Synthesis, Anti-HIV Evaluation, and Their Interaction with CXCR-4 Coreceptor", JOURNAL OF MEDICINAL CHEMISTRY (1999), 42(2), 229-241, XP002199037 *
SCHOLS, DOMINIQUE ET AL: "Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor Fusin/CXCR-4", ANTIVIRAL RES. (1997), 35(3), 147-156, XP002925073 *
See also references of WO0066112A1 *
XU, DAQIANG ET AL: "An expeditious synthesis of a biscyclam with an aromatic linker", TETRAHEDRON LETT. (1996), 37(30), 5301-5304, XP004029488 *

Also Published As

Publication number Publication date
EP1189609A1 (fr) 2002-03-27
WO2000066112A1 (fr) 2000-11-09
AU4692400A (en) 2000-11-17
JP2002543126A (ja) 2002-12-17

Similar Documents

Publication Publication Date Title
EP1189609A4 (fr) Antagonistes du recepteur cxcr-4 et mimetiques de thrombopoietine
PL348375A1 (en) Pyrrolidine derivatives-ccr-3 receptor antagonists
SG80041A1 (en) Muscarinic receptor antagonists
HUP0201524A3 (en) Bradykinin receptor antagonists
GB9903767D0 (en) Receptor assay
IL145761A0 (en) Il-8 receptor antagonists
IL146151A0 (en) Human-g-protein receptor
EP1248607A4 (fr) Antagonistes des recepteurs de l'urotensine ii
IL145762A0 (en) Il-8 receptor antagonists
PL351946A1 (en) Il-8 receptor antagonists
HUP0203805A3 (en) Ox2 receptor homologs
PL351947A1 (en) Il-8 receptor antagonists
GB0000474D0 (en) Receptor
EP1194143A4 (fr) Antagonistes du recepteur il-8
AU1252102A (en) Receptor
GB0026327D0 (en) Thrombin receptor antagonists
EP1185270A4 (fr) Antagonistes des recepteurs de il-8
AU5168900A (en) Il-8 receptor antagonists
HUP0202004A3 (en) Il-8 receptor antagonists
PL352218A1 (en) Il-8 receptor antagonists
ZA200003475B (en) Muscarinic receptor antagonists.
AU5622400A (en) Il-8 receptor antagonists
EP1237548A4 (fr) Antagonistes du recepteur de il-8
GB9811283D0 (en) Vironectin receptor antagonists
AU2512800A (en) Alpha1-adrenergic receptor antagonists

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011129

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07D 257/02 A, 7C 07D 401/10 B, 7C 07D 401/12 B, 7C 07D 401/14 B, 7C 07D 403/10 B, 7C 07D 403/12 B, 7C 07D 403/14 B, 7C 07D 405/12 B, 7C 07D 405/14 B, 7C 07D 409/14 B, 7C 07D 413/10 B, 7C 07D 417/10 B, 7A 61K 31/33 B, 7A 61K 31/395 B, 7A 61K 31/415 B, 7A 61K 31/425 B, 7A 61K 31/44 B, 7A 61K 31/445 B, 7A 61K 31/47 B, 7A 61K 31/495 B, 7A 61K 31/50 B, 7A 61K 31/505 B, 7A 61K 31/535 B, 7A 61K 31/54 B, 7A 61K 31/55 B

A4 Supplementary search report drawn up and despatched

Effective date: 20020912

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20030210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040922